Redwood Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Redwood Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,422	Closed	-$1.1M	–	331
2025 Q4	$1.1M	Buy	+1,422	New	+$966K	0.12%	134
2023 Q4	–	Sell	-2,381	Closed	-$1.96M	–	384
2023 Q3	$1.96M	Buy	+2,381	New	+$1.87M	0.17%	119
2022 Q4	–	Sell	-495	Closed	-$341K	–	290
2022 Q3	$341K	Buy	+495	New	+$312K	0.07%	181
2021 Q1	–	Sell	-1,379	Closed	-$666K	–	303
2020 Q4	$666K	Buy	+1,379	New	+$744K	0.11%	221

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Redwood Investment Management's REGN Position: Q1 2026 in Review

Redwood Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1,422 shares — an estimated $1.1M sold.

Redwood Investment Management first reported a position in REGN in Q4 2020 and held it in 4 quarters. The position peaked at $1.96M in Q3 2023. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Redwood Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Redwood Investment Management sold 1,422 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
Redwood Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Redwood Investment Management's Regeneron Pharmaceuticals position peaked at $1.96M in Q3 2023.
1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Redwood Investment Management's 13F filing for Q1 2026, filed 14 May 2026.